According to a recent LinkedIn post from Xeltis, the company is using the VASA 2026 meeting in Salt Lake City to showcase 12‑month pivotal data from a 120‑patient EU multicenter study of its aXess regenerative hemodialysis conduit. The presentation, delivered by Dr. Jason Wagner in an Innovation/Best Abstracts session, focuses on the concept of transforming polymer scaffolds into living tissue over time.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post indicates that Xeltis is both sponsoring VASA and exhibiting aXess at a conference booth, underscoring efforts to build clinical awareness and engagement among vascular access specialists. In parallel, the company reports hosting a working session with U.S. clinical coordinators to refine its U.S. clinical program around practical deployment of a regenerative hemodialysis conduit.
The post suggests that aXess is designed to be cannulation‑ready at implantation and to remodel into a patient’s own vessel, which could position the device as a differentiated option in vascular access if clinical outcomes are favorable. For investors, positive 12‑month pivotal data and active clinician outreach may signal progress toward broader commercialization, although regulatory timelines, reimbursement, and long‑term safety and durability will remain key determinants of future financial impact.